The coronavirus vaccine developed by China’s Sinovac has demonstrated an efficacy rate of 78 per cent in late-stage trials in Brazil, delivering a boost to China’s efforts to burnish its medical technology abroad and catch up with western vaccine manufacturers.
The results, announced on Wednesday by the Brazilian institute running the trial, pave the way for the rollout of the vaccine in Brazil and should please Beijing, which has made grand promises to manufacture and deliver vaccines across the developing world.
“The result means that the vaccine has a high degree of efficiency to protect the lives of Brazilians,” said João Doria, governor of São Paulo. “It is a historic moment.”
您已阅读21%（688字），剩余79%（2624字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。